Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia

Abstract

Patients with haematological malignancies and prolonged periods of neutropenia after chemotherapy are at high risk for severe bacterial and fungal infections. Those infections have long time been considered as a contraindication for subsequent haematopoietic stem cell transplantation (HCT). We conducted a prospective, non-randomized study of granulocyte transfusions (GTX) to control acute life-threatening infections (44 episodes) and to prevent recurrence of severe fungal infections during HCT or intensive chemotherapy (23 episodes). GTX achieved control in 82% (36/44) of acute life-threatening infections. No single reactivation of a previous infection occurred under prophylactic GTX (0/23). Median survival was 170 days in the interventional group and 185 days in the prophylactic group; death in both patient groups was mainly due to underlying progressive malignant disease. We conclude that under GTX, the infection-related mortality even in high-risk patients is low. Due to a secondary prophylaxis with GTX, haematopoietic allografts can be safely given to patients with previous fungal infections.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. 1.

    Adkins DR, Goodnough LT, Moellering J, Brown R, Khoury H, Vij R, DiPersio J (1999) Reduction in antibiotic utilization and of febrile days by transfusion of G-CSF mobilized prophylactic granulocyte components: a randomised study. Blood 94:590a

    Google Scholar 

  2. 2.

    Adkins DR, Goodnough LT, Shenoy S, Brown R, Moellering J, Khoury H, Vij R, DiPersio J (2000) Effect of leukocyte compatibility on neutrophil increment after transfusion of granulocyte colony-stimulating factor-mobilized prophylactic granulocyte transfusions and on clinical outcomes after stem cell transplantation. Blood 95:3605–3612

    CAS  PubMed  Google Scholar 

  3. 3.

    Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and haematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7–14

    Article  CAS  PubMed  Google Scholar 

  4. 4.

    Bensinger WI, Price TH, Dale DC, Appelbaum FR, Clift R, Lilleby K, Williams B, Storb R, Thomas ED, Buckner CD (1993) The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 81:1883–1888

    CAS  PubMed  Google Scholar 

  5. 5.

    Blum W, Hallem C, Vij R, Shenoy S, Goodnough L, Brown R, Khoury H, Westervelt P, DiPersio J, Adkins D (2001) Improved survival in allogeneic peripheral blood stem cell (PBSC) transplant recipients who received prophylactic granulocyte transfusions from HLA-matched donors: long-term follow-up. Blood 98:58a

    Google Scholar 

  6. 6.

    Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340

    CAS  PubMed  Google Scholar 

  7. 7.

    Bux J, Dielschneider T, Duscherer M, Edel E, Eichler H, Haas C, Moog R, Peschke H, Peters C, Ryzenkov I, Schlenke P, Ullrich H, Wiesneth M (2003) Tolerance of granulocyte donors towards granulocyte colony-stimulating factor stimulation and of patients towards granulocyte transfusions: results of a multicentre study. Vox Sang 85:322–325

    Article  CAS  PubMed  Google Scholar 

  8. 8.

    Caspar CB, Seger RA, Burger J, Gmür J (1993) Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocyte colony-stimulating factor. Blood 81:2866–2871

    CAS  PubMed  Google Scholar 

  9. 9.

    Cordonnier C, Maury S, Pautas C, Bastié JN, Chehata S, Castaigne S, Kuentz M, Bretagne S, Ribaud P (2004) Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 33:943–948

    Article  CAS  PubMed  Google Scholar 

  10. 10.

    Denning DW (1998) Invasive aspergillosis. Clin Infect Dis 26:781–803

    CAS  PubMed  Google Scholar 

  11. 11.

    Dignani MC, Anaissie EJ, Hester JP, O’Brien S, Vartivarian SE, Rex JH, Kantarjian H, Jendiroba DB, Lichtiger B, Nadersson BS, Freireich EJ (1997) Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions : a pilot study. Leukemia 11:1621–1630

    Article  CAS  PubMed  Google Scholar 

  12. 12.

    Freireich EJ, Levin RH, Whang J, Carbone PP, Bronson W, Morse EE (1964) The function and fate of transfused leukocytes from donors with chronic myelocytic leukemia in leukopenic patients. Ann NY Acad Sci 113:1081–1090

    CAS  PubMed  Google Scholar 

  13. 13.

    Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene R, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HAT, Troke PF, De Pauw B (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415

    Article  CAS  PubMed  Google Scholar 

  14. 14.

    Hermann S, Klein SA, Jacobi V, Thalhammer A, Bialleck H, Duchscherer M, Wassmann B, Hoelzer D, Martin H (2001) Older patients with high-risk fungal infections can be successfully allografted using non-myeloablative conditioning in combination with intensified supportive care regimens. Br J Haematol 113:446–454

    Article  CAS  PubMed  Google Scholar 

  15. 15.

    Hübel K, Carter RA, Liles WC, Dale DC, Price TH, Bowden RA, Rowley RD, Chauncey TR, Bensinger WI, Boeckh M (2002) Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion 42:1414–1421

    Article  PubMed  Google Scholar 

  16. 16.

    Illerhaus G, Wirth A, Dwenger A, Waller CF, Garbe A, Brass V, Lang H, Lange W (2002) Treatment and prophylaxis of severe infections in neutropenic patients by granulocyte transfusions. Ann Hematol 81:273–281

    Article  CAS  PubMed  Google Scholar 

  17. 17.

    Kerr JP, Liakopolou E, Brown J, Cornish JM, Fleming D, Massey E, Oakhill A, Pamphilon DH, Robinson SP, Totem A, Valencia AMP, Marks DI (2003) The use of stimulated granulocyte transfusions to prevent recurrence of past severe infections after allogenic stem cell transplantation. Br J Haematol 123:114–118

    Article  PubMed  Google Scholar 

  18. 18.

    Klein SA, Hermann S, Dietrich CF, Hoelzer D, Martin H (2002) Transplantation-related toxicity and acute intestinal graft-versus-host disease after conditioning regimens intensified with Rhenium 188-labeled anti-CD66 monoclonal antibody. Blood 99:2270–2271

    Article  CAS  PubMed  Google Scholar 

  19. 19.

    Lee JJ, Chung IJ, Park MR, Kook H, Hwang TJ, Ryang DW, Kim HJ (2001) Clinical efficacy of granulocyte transfusion therapy in patients with neutropenia-related infections. Leukemia 15:203-207

    Article  CAS  PubMed  Google Scholar 

  20. 20.

    Offner F, Cordonnier C, Ljungmann P, Prentice HG, Engelhard D, De Bacquer D, Meunier F, De Pauw B (1998) Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 26:1098–1103

    CAS  PubMed  Google Scholar 

  21. 21.

    Peters C, Minkov M, Matthes-Martin S, Pötschger U, Witt V, Mann G, Höcker P, Worel N, Stary J, Klingebiel T, Gadner H (1999) Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised patients. Br J Haematol 106:689–696

    Article  CAS  PubMed  Google Scholar 

  22. 22.

    Price TH, Raleigh AB, Boeckh M, Bux J, Nelson K, Liles C, Dale DC (2000) Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood 95:3302–3309

    CAS  PubMed  Google Scholar 

  23. 23.

    Robinson SP, Marks DI (2004) Granulocyte transfusions in the G-CSF era. Where do we stand? Bone Marrow Transplant 34:839–846

    Article  CAS  PubMed  Google Scholar 

  24. 24.

    Rutella S, Pierelli L, Piccirillo N, Sica S, Serafini R, Chiusolo P, Paladini U, Leone F, Zini G, D’Onofrio G, Leone G (2003) Efficacy of granulocyte transfusions for neutropenia-related infections: retrospective analysis of predictive factors. Cytotherapy 5:19–30

    Article  CAS  PubMed  Google Scholar 

  25. 25.

    Strauss RG (1995) Clinical perspectives of granulocyte transfusions: efficacy to date. J Clin Apher 10:114–118

    CAS  Google Scholar 

  26. 26.

    Vamvakas EC, Pineda AA (1996) Meta-analysis of clinical studies of the efficacy of granulocyte transfusions in the treatment of bacterial sepsis. J Clin Apher 11:1–9

    Article  CAS  Google Scholar 

  27. 27.

    Vij R, DiPersio JF, Venkatraman P, Trinkaus K, Goddnough LT, Brown RA, Khoury HJ, Devine SM, Oza A, Shenoy S, Blum W, Adkins D (2003) Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogenic peripheral blood stem cell transplantation. Blood 101:2067–2069

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by Knochenmarktransplantation/Gentherapie Frankfurt (KGF) e.V. The authors thank the haematology nursing staff for their excellent patient care.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Sabine Mousset.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Mousset, S., Hermann, S., Klein, S.A. et al. Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol 84, 734–741 (2005). https://doi.org/10.1007/s00277-005-1055-z

Download citation

Keywords

  • Granulocyte transfusion
  • Neutropenia
  • Stem cell transplantation
  • Fungal infection
  • Cellular therapies